Krystal Biotech, Inc. Common Stock (KRYS) is a publicly traded Healthcare sector company. As of May 21, 2026, KRYS trades at $318.29 with a market cap of $8.60B and a P/E ratio of 38.58. KRYS moved +3.00% today. Year to date, KRYS is +23.43%; over the trailing twelve months it is +129.62%. Its 52-week range spans $122.80 to $319.48. Analyst consensus is strong buy with an average price target of $316.00. Rallies surfaces KRYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Krystal Biotech jumps as Q1 VYJUVEK revenue hits $116.4M, pipeline catalysts build: Krystal Biotech shares rose about 3.9% on May 5, 2026 after reporting Q1 2026 results showing $116.4 million in VYJUVEK net product revenue (+32% YoY) and $55.9 million net income. Investors also focused on FDA platform technology designations for KB407 and KB111 and multiple 2026 registrational data readouts.
| Metric | Value |
|---|---|
| Price | $318.29 |
| Market Cap | $8.60B |
| P/E Ratio | 38.58 |
| EPS | $7.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $319.48 |
| 52-Week Low | $122.80 |
| Volume | 170.35K |
| Avg Volume | 0 |
| Revenue (TTM) | $417.30M |
| Net Income | $225.03M |
| Gross Margin | 0.00% |
10 analysts cover KRYS: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $316.00.